Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

PRG Nutraceuticals UK Launch

1 Oct 2009 10:34

RNS Number : 0408A
ReGen Therapeutics PLC
01 October 2009
 



1 October 2009

For immediate release

ReGen Announces PRG Nutraceuticals Limited UK Launch

ReGen Therapeutics Plc ('ReGen' or the 'Company') is pleased to announce that it has been notified by PRG Nutraceuticals Limited that it has launched Colostrinin™* as 'MemoryAid' in the UK.

Announcing the launch, PRG Managing Director Dr Peter Garrod said:-

"Every day we hear more evidence of how the population faces a terrible future as our brains become increasingly affected by conditions associated with getting old. MemoryAid contains a complex that we believe will help people to fight the onset of the problems that result from our brains undergoing the normal ageing process. Many years of research into the complex has shown that it promotes antioxidant activity, can reduce the toxicity of beta amyloid and protects the brain against the damaging effects of free radicals, all of which manifest themselves in the problems that occur as our brains naturally age. The complex has also been shown to increase the average lifespan of living cells and reduces premature ageing, which will also benefit consumers.

MemoryAid is targeted at a wide spectrum of people, both the older community, who may already be noticing that their brains are not functioning in the manner they are normally accustomed to, and at younger adults, who just want to protect themselves against memory deterioration in the future.

We are very excited by the benefits of MemoryAid and believe that it has a bright future on everyone's breakfast table."

MemoryAid is available on the internet at www.memoryaid.com or by contacting PRG on 01580 891349 or mobile 07785 740421.  

MemoryAid

Support for healthy brain ageing

Maintains normal mental function and supports healthy brain ageing.

Increases the average lifespan of living cells.

Reduces the aggregation and toxicity of beta amyloid, a feature of neurodegenerative conditions.

Protects the brain against the damaging effects of many free radicals

*Colostrinin™ is a proline-rich polypeptide complex that maintains normal mental function and supports healthy brain ageing.

For further information:

Dr Peter Garrod

PRG Nutraceuticals Ltd

Tel. 01580 891349 / 07785 740421

Percy Lomax ReGen Therapeutics Plc Tel No 020 7153 4920

Roland Cornish/Felicity Geidt Beaumont Cornish Limited Tel No 020 7628 3396

Nick Bealer/David Scott Alexander David Tel No 020 7448 9820 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGCBDGIDGGGCB
Date   Source Headline
17th Sep 20207:00 amRNSClinical Study with Nasally Administered Foralumab
16th Sep 20209:05 amRNSSecond Price Monitoring Extn
16th Sep 20209:00 amRNSPrice Monitoring Extension
16th Sep 20207:00 amRNSDemerger of StemPrintER and Distribution in Specie
7th Sep 202011:05 amRNSSecond Price Monitoring Extn
7th Sep 202011:00 amRNSPrice Monitoring Extension
2nd Sep 20204:41 pmRNSSecond Price Monitoring Extn
2nd Sep 20204:35 pmRNSPrice Monitoring Extension
2nd Sep 20202:06 pmRNSSecond Price Monitoring Extn
2nd Sep 20202:00 pmRNSPrice Monitoring Extension
28th Aug 202012:04 pmRNSHolding(s) in Company
28th Aug 202010:30 amRNSADS Registration Statement Filing Clarification
27th Aug 20204:00 pmRNSExercise of Warrants and Issue of Equity
27th Aug 20207:00 amRNSTiziana CEO Interview
26th Aug 20207:00 amRNSGrant of Options - Director Dealings
24th Aug 20207:00 amRNSPatent Granted for Anti-IL-6/IL-6
21st Aug 20207:00 amRNSPatent Granted for Milciclib
20th Aug 20207:00 amRNSUpdate - Scientific Advisory Board
18th Aug 20209:05 amRNSSecond Price Monitoring Extn
18th Aug 20209:00 amRNSPrice Monitoring Extension
18th Aug 20207:00 amRNSPatent Granted for Foralumab
11th Aug 20208:49 amRNSBTIG's Virtual Biotechnology Conference
10th Aug 20207:00 amRNSHolding(s) in Company
5th Aug 20204:00 pmRNSClosing of $57.25 Million Offering
4th Aug 20207:00 amRNSExpedited Clinical Development Plan
3rd Aug 20207:00 amRNSIssue of Equity
31st Jul 20205:00 pmRNSTotal Voting Rights
31st Jul 20204:41 pmRNSSecond Price Monitoring Extn
31st Jul 20204:35 pmRNSPrice Monitoring Extension
31st Jul 20207:00 amRNSSubmission of a Patent Application for Foralumab
30th Jul 20204:30 pmRNSProposed Admission to the Official List
30th Jul 202011:53 amRNSUpdate on Timings and Corporate Actions
30th Jul 20207:00 amRNSInvestor Webinar to Provide Corporate Updates
29th Jul 20202:05 pmRNSSecond Price Monitoring Extn
29th Jul 20202:00 pmRNSPrice Monitoring Extension
24th Jul 20207:00 amRNSExercise of Warrants and Issue of Equity
20th Jul 20202:51 pmRNSDirector Appointment
20th Jul 20209:05 amRNSSecond Price Monitoring Extn
20th Jul 20209:00 amRNSPrice Monitoring Extension
16th Jul 202011:39 amRNSResult of AGM
16th Jul 20207:00 amRNSSubmission of Patent Application
15th Jul 20204:29 pmRNSChange to ADS Ratio - Updated
15th Jul 20201:00 pmRNSChange to ADS Ratio
14th Jul 20209:06 amRNSSecond Price Monitoring Extn
14th Jul 20209:00 amRNSPrice Monitoring Extension
13th Jul 20204:41 pmRNSSecond Price Monitoring Extn
13th Jul 20204:36 pmRNSPrice Monitoring Extension
10th Jul 20206:01 pmRNSInterview to Air on Bloomberg International
1st Jul 20207:00 amRNSTotal Voting Rights and StemPrintER Update
29th Jun 202011:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.